637 related articles for article (PubMed ID: 31730497)
1. Predictors of good response to conventional synthetic DMARDs in early seronegative rheumatoid arthritis: data from the ESPOIR cohort.
Lukas C; Mary J; Debandt M; Daïen C; Morel J; Cantagrel A; Fautrel B; Combe B
Arthritis Res Ther; 2019 Nov; 21(1):243. PubMed ID: 31730497
[TBL] [Abstract][Full Text] [Related]
2. Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting.
Alten R; Burkhardt H; Feist E; Krüger K; Rech J; Rubbert-Roth A; Voll RE; Elbez Y; Rauch C
Arthritis Res Ther; 2018 Jan; 20(1):1. PubMed ID: 29329602
[TBL] [Abstract][Full Text] [Related]
3. Outcome of patients with early arthritis without rheumatoid factor and ACPA and predictors of rheumatoid arthritis in the ESPOIR cohort.
Mouterde G; Rincheval N; Lukas C; Daien C; Saraux A; Dieudé P; Morel J; Combe B
Arthritis Res Ther; 2019 Jun; 21(1):140. PubMed ID: 31171038
[TBL] [Abstract][Full Text] [Related]
4. Triple Oral Therapy Versus Antitumor Necrosis Factor Plus Methotrexate (MTX) in Patients with Rheumatoid Arthritis and Inadequate Response to MTX: A Systematic Literature Review.
Mary J; De Bandt M; Lukas C; Morel J; Combe B
J Rheumatol; 2017 Jun; 44(6):773-779. PubMed ID: 28412710
[TBL] [Abstract][Full Text] [Related]
5. Five-year favorable outcome of patients with early rheumatoid arthritis in the 2000s: data from the ESPOIR cohort.
Combe B; Rincheval N; Benessiano J; Berenbaum F; Cantagrel A; Daurès JP; Dougados M; Fardellone P; Fautrel B; Flipo RM; Goupille P; Guillemin F; Le Loët X; Logeart I; Mariette X; Meyer O; Ravaud P; Saraux A; Schaeverbeke T; Sibilia J
J Rheumatol; 2013 Oct; 40(10):1650-7. PubMed ID: 23950185
[TBL] [Abstract][Full Text] [Related]
6. Matrix to predict rapid radiographic progression of early rheumatoid arthritis patients from the community treated with methotrexate or leflunomide: results from the ESPOIR cohort.
Fautrel B; Granger B; Combe B; Saraux A; Guillemin F; Le Loet X
Arthritis Res Ther; 2012 Nov; 14(6):R249. PubMed ID: 23164197
[TBL] [Abstract][Full Text] [Related]
7. Short-term efficacy of etanercept plus methotrexate vs combinations of disease-modifying anti-rheumatic drugs with methotrexate in established rheumatoid arthritis.
Fleischmann R; Koenig AS; Szumski A; Nab HW; Marshall L; Bananis E
Rheumatology (Oxford); 2014 Nov; 53(11):1984-93. PubMed ID: 24907147
[TBL] [Abstract][Full Text] [Related]
8. Association of Baseline Peptidylarginine Deiminase 4 Autoantibodies With Favorable Response to Treatment Escalation in Rheumatoid Arthritis.
Darrah E; Yu F; Cappelli LC; Rosen A; O'Dell JR; Mikuls TR
Arthritis Rheumatol; 2019 May; 71(5):696-702. PubMed ID: 30507066
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of methotrexate with step-down glucocorticoid remission induction (COBRA Slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1-year results of CareRA, a randomised pragmatic open-label superiority trial.
Verschueren P; De Cock D; Corluy L; Joos R; Langenaken C; Taelman V; Raeman F; Ravelingien I; Vandevyvere K; Lenaerts J; Geens E; Geusens P; Vanhoof J; Durnez A; Remans J; Vander Cruyssen B; Van Essche E; Sileghem A; De Brabanter G; Joly J; Meyfroidt S; Van der Elst K; Westhovens R
Ann Rheum Dis; 2017 Mar; 76(3):511-520. PubMed ID: 27432356
[TBL] [Abstract][Full Text] [Related]
10. Anti-cyclic citrullinated peptide antibodies, 28-joint Disease Activity Score, and magnetic resonance imaging bone oedema at baseline predict 11 years' functional and radiographic outcome in early rheumatoid arthritis.
Hetland ML; Østergaard M; Stengaard-Pedersen K; Junker P; Ejbjerg B; Jacobsen S; Ellingsen T; Lindegaard H; Pødenphant J; Vestergaard A; Jurik AG; Krogh NS; Hørslev-Petersen K;
Scand J Rheumatol; 2019 Jan; 48(1):1-8. PubMed ID: 30101636
[TBL] [Abstract][Full Text] [Related]
11. Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial.
Verschueren P; De Cock D; Corluy L; Joos R; Langenaken C; Taelman V; Raeman F; Ravelingien I; Vandevyvere K; Lenaerts J; Geens E; Geusens P; Vanhoof J; Durnez A; Remans J; Vander Cruyssen B; Van Essche E; Sileghem A; De Brabanter G; Joly J; Meyfroidt S; Van der Elst K; Westhovens R
Ann Rheum Dis; 2015 Jan; 74(1):27-34. PubMed ID: 25359382
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the long-term outcome for patients with rheumatoid arthritis with persistent moderate disease activity or disease remission during the first year after diagnosis: data from the ESPOIR cohort.
Combe B; Logeart I; Belkacemi MC; Dadoun S; Schaeverbeke T; Daurès JP; Dougados M
Ann Rheum Dis; 2015 Apr; 74(4):724-9. PubMed ID: 24399234
[TBL] [Abstract][Full Text] [Related]
13. An open-label randomized controlled trial of DMARD withdrawal in RA patients achieving therapeutic response with certolizumab pegol combined with DMARDs.
Pope J; Rampakakis E; Vaillancourt J; Bessette L; Lazovskis J; Haraoui B; Sampalis JS
Rheumatology (Oxford); 2020 Jul; 59(7):1522-1528. PubMed ID: 31628486
[TBL] [Abstract][Full Text] [Related]
14. Disability measured by the modified health assessment questionnaire in early rheumatoid arthritis: prognostic factors after two years of follow-up.
Graell E; Vazquez I; Larrosa M; Rodríguez-Cros JR; Hernández MV; Gratacós J; Gómez A; Cañete JD; Gómez-Puerta JA; Sanmartí R
Clin Exp Rheumatol; 2009; 27(2):284-91. PubMed ID: 19473570
[TBL] [Abstract][Full Text] [Related]
15. Clinical deep remission and related factors in a large cohort of patients with rheumatoid arthritis.
Liu JJ; Li R; Gan YZ; Zhang RJ; Li J; Cai YM; Zhao JX; Liao H; Xu J; Shi LJ; Li J; Li SG; Sun XL; He J; Liu X; Ye H; Li ZG
Chin Med J (Engl); 2019 May; 132(9):1009-1014. PubMed ID: 30946065
[TBL] [Abstract][Full Text] [Related]
16. The effects of disease-modifying anti-rheumatic drugs on the Health Assessment Questionnaire score. Lessons from the leflunomide clinical trials database.
Scott DL; Strand V
Rheumatology (Oxford); 2002 Aug; 41(8):899-909. PubMed ID: 12154207
[TBL] [Abstract][Full Text] [Related]
17. Three out of four disease-modifying anti-rheumatic drug-naïve rheumatoid arthritis patients meet 28-joint Disease Activity Score remission at 12 months: results from the FIN-ERA cohort.
Rannio T; Asikainen J; Hannonen P; Yli-Kerttula T; Ekman P; Pirilä L; Kuusalo L; Mali M; Puurtinen-Vilkki M; Kortelainen S; Paltta J; Taimen K; Kauppi M; Laiho K; Nyrhinen S; Mäkinen H; Isomäki P; Uotila T; Aaltonen K; Kautiainen H; Sokka T
Scand J Rheumatol; 2017 Nov; 46(6):425-431. PubMed ID: 28367663
[TBL] [Abstract][Full Text] [Related]
18. Systematic review and meta-analysis of the efficacy and safety of leflunomide and methotrexate in the treatment of rheumatoid arthritis.
Alfaro-Lara R; Espinosa-Ortega HF; Arce-Salinas CA;
Reumatol Clin (Engl Ed); 2019; 15(3):133-139. PubMed ID: 28867467
[TBL] [Abstract][Full Text] [Related]
19. Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in Phase III randomised clinical trials of tofacitinib.
Bird P; Hall S; Nash P; Connell CA; Kwok K; Witcombe D; Thirunavukkarasu K
RMD Open; 2019; 5(1):e000742. PubMed ID: 30886732
[TBL] [Abstract][Full Text] [Related]
20. Smoking and response to rituximab in rheumatoid arthritis: results from an international European collaboration.
Chatzidionysiou K; Lukina G; Gabay C; Hetland ML; Hauge EM; Pavelka K; Nordström D; Canhão H; Tomsic M; Rotar Z; Lie E; Kvien TK; van Vollenhoven RF; Saevarsdottir S
Scand J Rheumatol; 2019 Jan; 48(1):17-23. PubMed ID: 30260261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
